Sign in

Private company

Silk Road Medical Inc

In its 2024 annual report the company says: “We are a medical device company focused on reducing the risk of stroke and its devastating impact. We have obtained U.S. Food and Drug Administration, or FDA, approvals, secured specific Medicare reimbursement coverage, and commercialize products engineered and indicated specifically for transcarotid use, in patients who require carotid revascularization and who meet certain treatment criteria.”4 It is headquartered in Sunnyvale, United States.2

Last updated Oct 21, 2026.

Overview

  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersSunnyvale, United States2
  • Incorporated inDE3
  • Business address1213 Innsbruck Dr., Sunnyvale, Ca 94089-29183
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI549300VL8KC0ZPDQHE142
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 43199232

See how the biggest companies compare on our leaderboards

We are a medical device company focused on reducing the risk of stroke and its devastating impact. We believe a key to stroke prevention is minimally-invasive and technologically advanced intervention to safely and effectively treat carotid artery disease, one of the leading causes of stroke. Our business is focused on a relatively new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which we seek to establish as the standard of care.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

71.7%Gross margin5
-33.5%Operating margin5
-31.5%Net margin5
27.8%Revenue growth, 20235
-36.9%Return on equity5
0.50×Debt to equity5
-$33.5MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue21¢$50.0M
  • Research and development17¢$41.3M
  • Selling, general and admin60¢$145.0M
  • Interest3¢$6.9M
  • Income tax0¢$43.0K

Out of $177.1M in revenue.5 The company lost money this year.

Financial statements

Revenue6785$177.1M in 2023+413% since 2018
0$50.0M$100.0M$150.0M$200.0M2018: $34.6M$34.6M20182019: $63.4M$63.4M2019+83%2020: $75.2M$75.2M2020+19%2021: $101.5M$101.5M2021+35%2022: $138.6M$138.6M2022+37%2023: $177.1M$177.1M2023+28%
Gross profit6785$127.1M in 2023+437% since 2018
0$50.0M$100.0M$150.0M2018: $23.7M$23.7M20182019: $47.4M$47.4M2019+100%2020: $53.9M$53.9M2020+14%2021: $76.0M$76.0M2021+41%2022: $100.8M$100.8M2022+33%2023: $127.1M$127.1M2023+26%
Operating income6785-$59.3M in 2023+177% since 2018
-$60.0M-$40.0M-$20.0M02018: -$21.4M-$21.4M20182019: -$28.1M-$28.1M2019+31%2020: -$42.9M-$42.9M2020+53%2021: -$47.5M-$47.5M2021+11%2022: -$52.0M-$52.0M2022+10%2023: -$59.3M-$59.3M2023+14%
Net income6785-$55.7M in 2023+48% since 2018
-$60.0M-$40.0M-$20.0M02018: -$37.6M-$37.6M20182019: -$52.4M-$52.4M2019+39%2020: -$47.4M-$47.4M2020−10%2021: -$49.8M-$49.8M2021+5%2022: -$55.0M-$55.0M2022+10%2023: -$55.7M-$55.7M2023+1%
Fiscal year2017201820192020202120222023
Revenue$34.6M6$63.4M7$75.2M8$101.5M5$138.6M5$177.1M5
Cost of revenue$10.9M6$15.9M7$21.3M8$25.4M5$37.9M5$50.0M5
Gross profit$23.7M6$47.4M7$53.9M8$76.0M5$100.8M5$127.1M5
Research and development$10.3M6$12.3M7$21.3M8$27.1M5$36.4M5$41.3M5
Selling, general and admin$34.8M6$63.2M7$75.5M8$96.4M5$116.3M5$145.0M5
Operating expenses$123.5M5$152.8M5$186.4M5
Operating income-$21.4M6-$28.1M7-$42.9M8-$47.5M5-$52.0M5-$59.3M5
Interest$4.4M6$5.0M7$4.4M8$2.5M5$5.1M5$6.9M5
Income before tax-$49.8M5-$55.0M5-$55.7M5
Income tax$14.0K6$8.0K7$11.0K8$20.0K5$29.0K5$43.0K5
Net income-$37.6M6-$52.4M7-$47.4M8-$49.8M5-$55.0M5-$55.7M5
Earnings per share-$1.448-$1.445-$1.545-$1.445
Earnings per share (diluted)-$1.448-$1.445-$1.545-$1.445
Shares (weighted, basic)34.6M shares535.8M shares538.8M shares5
Shares (weighted, diluted)34.6M shares535.8M shares538.8M shares5

Compare Silk Road Medical Inc with another company

Corporate structure

Silk Road Medical Inc is part of a group headed by Boston Scientific. 140 entities, 44 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Silk Road Medical Inc

  • Goldman Sachs Filed SC 13G/A on Silk Road Medical Inc, latest Nov 5, 2024 (2 filings since Feb 5, 2024)
  • Magnetar Financial LLC Filed SC 13D/A on Silk Road Medical Inc, latest Sep 19, 2024 (2 filings since Aug 12, 2024)
  • Capital World Investors Filed SC 13G/A on Silk Road Medical Inc, latest Jul 10, 2024 (3 filings since Feb 11, 2022)
  • WASATCH ADVISORS LP Filed SC 13G/A on Silk Road Medical Inc, latest Jul 1, 2024 (6 filings since Nov 9, 2021)
  • VANGUARD GROUP INC Filed SC 13G/A on Silk Road Medical Inc, latest Feb 13, 2024 (3 filings since Feb 10, 2022)
  • BlackRock Filed SC 13G/A on Silk Road Medical Inc, latest Jan 26, 2024 (3 filings since Feb 3, 2022)
  • James E. Flynn Filed SC 13G on Silk Road Medical Inc, latest Oct 20, 2023 (3 filings since Jan 24, 2022)
  • AllianceBernstein Filed SC 13G/A on Silk Road Medical Inc, latest Aug 10, 2023 (4 filings since Feb 14, 2022)
  • Boston Scientific Malborough, Massachusetts, United States
    • Silk Road Medical Inc Sunnyvale, California, United States
    • Apama Medical (United States) Subsidiary
    • Boston Scientific (Barbados) Subsidiary · Bridgetown, Barbados
    • 165Bio Inc. Subsidiary · Delaware, United States
    • 34 Biomedical Merger Corp. Subsidiary · Delaware, United States
    • 9357-1867 Quebec Inc., d/b/a Cryterion Medical Enterprise Canada Subsidiary · Canada
    • Ablacon GmbH (Germany) Ablacon SA, en liquidation Subsidiary · Switzerland
    • Acotec Scientific Holdings Limited Subsidiary · Cayman Islands
    • Acurate Industria e Comercio Ltda. Subsidiary · Brazil
    • American Medical Systems Europe B.V. Subsidiary · Marlborough, Massachusetts, United States
    • Anchors (HZ) Medical Technology Co., Ltd. Subsidiary · China
    • Anrei Medical Device (Hangzhou) Co., Ltd. Subsidiary · China
    • Anrei Medical Device (Tianjin) Co., Ltd. Subsidiary · China
    • Apollo Endosurgery UK Ltd Subsidiary · United Kingdom
    • Apollo Endosurgery US, Inc. Subsidiary · Delaware, United States
    • Apollo Endosurgery, Inc. Subsidiary · Delaware, United States
    • Axonics Modulation Technologies, U.K. Limited Subsidiary · United Kingdom
    • Axonics Women’s Health Limited Subsidiary · United Kingdom
    • Axonics, Inc. (Delaware) Axonics Modulation Technologies Australia Pty Ltd Subsidiary · Australia
    • Baylis Medical Company Inc. Subsidiary · Canada
    • Baylis Medical USA Inc. Subsidiary · Delaware, United States
    • Biocompatibles UK Limited Subsidiary · United Kingdom
    • Biocompatibles, Inc. Subsidiary · Delaware, United States
    • Bolt Medical, Inc. Subsidiary · Delaware, United States
    • Boston Scientific (Belgium) Subsidiary · Belgium
    • and 111 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Silk Road Medical Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$15.7M5 Dec 31, 2023$14.4M5 Dec 31, 2022+8.8%
Accumulated depreciation$7.9M5 Dec 31, 2023$5.4M5 Dec 31, 2022+47.7%
Property and equipment, net$8.1M5 Dec 31, 2023$9.4M5 Dec 31, 2022−13.4%
Operating-lease assets (leased space)$6.5M5 Dec 31, 2023$5.1M5 Dec 31, 2022+27.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$20.2M5 Dec 31, 2023$55.4M5 Dec 31, 2022−63.5%
Marketable securities, current$161.3M5 Dec 31, 2023$158.3M5 Dec 31, 2022+1.9%
Debt securities available for sale$190.2M5 Dec 31, 2023$213.5M5 Dec 31, 2022−10.9%
Long-term investments$9.5M5 Dec 31, 2023$06 Dec 31, 2020

Inventory

ItemLatestA year beforeChange
Inventory, total$29.9M5 Dec 31, 2023$19.3M5 Dec 31, 2022+54.9%
Raw materials$6.5M5 Dec 31, 2023$4.9M5 Dec 31, 2022+32.5%
Work in process$05 Dec 31, 2023$05 Dec 31, 2022
Finished goods$23.4M5 Dec 31, 2023$14.4M5 Dec 31, 2022+62.5%

Leadership

Who has led Silk Road Medical Inc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Erica J. Rogers2019–2023
  2. Chas McKhann2023–2024

President

  1. Erica J. Rogers2019–2023

Chief financial officer

  1. Lucas W. Buchanan2019–2024

Chief operating officer

  1. Lucas W. Buchanan2020–2024
20202025
Board members and other officers (15)

Timeline

  1. Sep 17, 20248-K Ended a material agreement; Completed an acquisition or sale; Debt or obligation accelerated29
  2. Sep 13, 20248-K Other events30
  3. Sep 6, 20248-K Shareholder vote31
  4. Aug 9, 20248-K Other events32
  5. Aug 7, 20248-K Results of operations33
  6. Jun 20, 20248-K Shareholder vote34
  7. Jun 18, 20248-K Entered a material agreement; Other events35
  8. Apr 30, 20248-K Results of operations36
  9. Feb 28, 20248-K Results of operations37
  10. Jan 9, 20248-K Regulation FD disclosure38
  11. Nov 8, 20238-K Results of operations39
  12. Nov 3, 2023New chief executive Chas McKhann becomes CEO12
  13. Nov 2, 20238-K Executive or director change; Regulation FD disclosure40
  14. Apr 3, 2019New chief executive Erica J. Rogers becomes CEO13
  15. Mar 21, 2007Founded Silk Road Medical Inc is founded2

Calendar

When it reported results

  1. Aug 7, 2024Reported quarterly or annual results33
  2. Apr 30, 2024Reported quarterly or annual results36
  3. Feb 28, 2024Reported quarterly or annual results37
  4. Nov 8, 2023Reported quarterly or annual results39
  5. Oct 10, 2023Reported quarterly or annual results41
  6. Aug 1, 2023Reported quarterly or annual results42
  7. May 9, 2023Reported quarterly or annual results43
  8. Feb 28, 2023Reported quarterly or annual results44

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

244 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 28 major events, 125 insider forms, 26 large holders, 53 other. The latest 20:

  1. Nov 5, 2024SC 13G/A SILKROAD EDGAR
  2. Sep 27, 202415-12G EDGAR
  3. Sep 23, 2024EFFECT EDGAR
  4. Sep 19, 2024SC 13D/A EDGAR
  5. Sep 18, 20244 EDGAR
  6. Sep 18, 20244 EDGAR
  7. Sep 18, 20244 EDGAR
  8. Sep 18, 20244 EDGAR
  9. Sep 18, 20244 EDGAR
  10. Sep 18, 20244 EDGAR
  11. Sep 18, 20244 EDGAR
  12. Sep 18, 20244 EDGAR
  13. Sep 18, 20244 EDGAR
  14. Sep 18, 20244 EDGAR
  15. Sep 18, 20244 EDGAR
  16. Sep 18, 20244 EDGAR
  17. Sep 18, 20244 EDGAR
  18. Sep 17, 2024S-8 POS EDGAR
  19. Sep 17, 2024S-8 POS EDGAR
  20. Sep 17, 2024S-8 POS EDGAR

The 244 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

72 open-market trades by officers, directors and large owners since October 2021: 2 buys and 70 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 19, 2024Klemz Kevin MEVP/Chief Legal Officer/Sec.Sale2,268$27.10$61.5KForm 4
Jul 3, 2024Davis Andrew S.Chief Commercial OfficerSale66$27.00$1.8KForm 4
Mar 5, 2024Ballinger Kevin J.DirectorBuy11,700$16.99$198.8KForm 4
Mar 5, 2024Buchanan Lucas W.COO & CFOSale9,877$17.17$169.6KForm 4
Mar 5, 2024Ruedy RichardEVPClin&Reg.Affairs&QASale3,800$17.17$65.2KForm 4
Mar 5, 2024Davis Andrew S.Chief Commercial OfficerSale5,481$17.17$94.1KForm 4
Mar 5, 2024Jones Marie L.VP, Finance and CAOSale2,602$17.17$44.7KForm 4
Mar 5, 2024Klemz Kevin MEVP/Chief Legal Officer/Sec.Sale2,497$17.17$42.9KForm 4
Feb 29, 2024Ruedy RichardEVPClin&Reg.Affairs&QASale3,000$22.25$66.8KForm 4
Oct 27, 2023Jones Marie L.VP, Finance and CAOSale656$6.61$4.3KForm 4
Oct 4, 2023Buchanan Lucas W.COO & CFOSale2,662$15.22$40.5KForm 4
Aug 17, 2023Klemz Kevin MEVP/Chief Legal Officer/Sec.Sale1,539$20.11$30.9KForm 4
Aug 3, 2023Davis Andrew S.Chief Commercial OfficerSale6,587$22.13$145.8KForm 4
Jul 11, 2023Rogers Erica J.President and CEOSale1,000$31.56$31.6KForm 4
Jul 6, 2023Davis Andrew S.Chief Commercial OfficerSale69$30.79$2.1KForm 4
Jun 12, 2023Rogers Erica J.President and CEOSale1,000$32.13$32.1KForm 4
May 11, 2023Rogers Erica J.President and CEOSale3,000$35.51$106.5KForm 4
May 1, 2023Davis Andrew S.Chief Commercial OfficerSale6,753$44.51$300.6KForm 4
Apr 17, 2023WEATHERMAN ELIZABETH HDirectorSale5,000$41.91$209.6KForm 4
Apr 11, 2023Rogers Erica J.President and CEOSale6,000$39.77$238.6KForm 4

All 72 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Silk Road Medical Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSilk Road Medical Inc1
  • CIK0001397702
  • Employer ID (EIN)20-87776221
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address1213 Innsbruck Dr., Sunnyvale, CA 94089-29181
  • Phone65056690601
  • Shares outstanding40,632,143 as of Jul 31, 202410
  • Public float$1.2B as of Jun 30, 20235
  • On EDGAR sinceApr 16, 20071
  • Filings521 in all: 4 (274), 8-K (57), SC 13G/A (25), 3 (23), 10-Q (17), 144 (15), SC 13G (12), CORRESP (8)1
    All 45 form types

    DEFA14A (8), D (6), S-8 (6), S-8 POS (6), 10-K (5), DEF 14A (5), 424B5 (4), UPLOAD (4), 4/A (3), EFFECT (3), S-1/A (3), SD (3), 424B4 (2), ARS (2), CT ORDER (2), DRS (2), FWP (2), REGDEX (2), S-1 (2), S-3ASR (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 8-A12B (1), 8-K/A (1), CERT (1), DEFM14A (1), DEFR14A (1), POS AM (1), PRE 14A (1), PREM14A (1), REGDEX/A (1), RW (1), S-1MEF (1), S-3 (1), SC 13D (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Feb 28, 2024
    Quarterly report (10-Q) Aug 7, 2024
    Proxy statement (DEF 14A) Apr 26, 2024
    Latest 8-K (8-K) Sep 17, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52